Daniel James George, MD

Professor of Medicine
Professor in Surgery
Member of the Duke Cancer Institute
Campus mail Duke Box 103861, Durham, NC 27710
Phone (919) 668-4615
Email address daniel.george@duke.edu

Education and Training

  • Fellow in Medical Oncology, Medicine, Johns Hopkins University, 1995 - 1998
  • Medical Resident, Medicine, Johns Hopkins University, 1992 - 1995
  • M.D., Duke University, 1992

Grants

Publications

Labriola, Matthew K., and Daniel J. George. “Setting a new standard for long-term survival in metastatic kidney cancer.” Cancer 128, no. 11 (June 1, 2022): 2058–60. https://doi.org/10.1002/cncr.34177.

PMID
35383907
Full Text

Bu, Jiyoon, Woo-Jin Jeong, Roya Jafari, Luke J. Kubiatowicz, Ashita Nair, Michael J. Poellmann, Rachel S. Hong, et al. “Bimodal liquid biopsy for cancer immunotherapy based on peptide engineering and nanoscale analysis.” Biosens Bioelectron 213 (June 1, 2022): 114445. https://doi.org/10.1016/j.bios.2022.114445.

PMID
35679646
Full Text

Zhang, Tian, Julie Kephart, Elizabeth Bronson, Monika Anand, Christine Daly, Ivan Spasojevic, Subha Bakthavatsalam, et al. “Prospective clinical trial of disulfiram plus copper in men with metastatic castration-resistant prostate cancer.” Prostate 82, no. 7 (May 2022): 858–66. https://doi.org/10.1002/pros.24329.

PMID
35286730
Full Text

Spees, Lisa P., Michaela A. Dinan, Bradford E. Jackson, Christopher D. Baggett, Lauren E. Wilson, Melissa A. Greiner, Deborah R. Kaye, et al. “Patient- And Provider-Level Predictors of Survival Among Patients With Metastatic Renal Cell Carcinoma Initiating Oral Anticancer Agents.” Clin Genitourin Cancer, April 25, 2022. https://doi.org/10.1016/j.clgc.2022.04.010.

PMID
35595633
Full Text

Zheng, Jia, Fanny Sampurno, Daniel J. George, Alicia K. Morgans, Hannah Nguyen, Janet L. Abrahm, Anders Bjartell, et al. “Establishing metastatic prostate cancer quality indicators using a modified Delphi approach.” Clin Genitourin Cancer 20, no. 2 (April 2022): e151–57. https://doi.org/10.1016/j.clgc.2021.11.018.

PMID
35135748
Full Text

Brown, Landon C., Susan Halabi, Jason A. Somarelli, Michael Humeniuk, Yuan Wu, Taofik Oyekunle, Lauren Howard, et al. “A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer.” Prostate Cancer Prostatic Dis, March 15, 2022. https://doi.org/10.1038/s41391-022-00524-7.

PMID
35292724
Full Text

Emamekhoo, Hamid, Mark R. Olsen, Bradley C. Carthon, Alexandra Drakaki, Ivor J. Percent, Ana M. Molina, Daniel C. Cho, et al. “Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920.” Cancer 128, no. 5 (March 1, 2022): 966–74. https://doi.org/10.1002/cncr.34016.

PMID
34784056
Full Text

Smith, Matthew R., Howard I. Scher, Shahneen Sandhu, Eleni Efstathiou, Primo N. Lara, Evan Y. Yu, Daniel J. George, et al. “Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial.” Lancet Oncol 23, no. 3 (March 2022): 362–73. https://doi.org/10.1016/S1470-2045(21)00757-9.

PMID
35131040
Full Text

Harrison, Michael R., Paul G. Davis, Michel G. Khouri, David B. Bartlett, Rajan T. Gupta, Andrew J. Armstrong, Megan A. McNamara, et al. “A randomized controlled trial comparing changes in fitness with or without supervised exercise in patients initiated on enzalutamide and androgen deprivation therapy for non-metastatic castration-sensitive prostate cancer (EXTEND).” Prostate Cancer Prostatic Dis 25, no. 1 (March 2022): 58–64. https://doi.org/10.1038/s41391-022-00519-4.

PMID
35273377
Full Text

Kaye, Deborah R., Lauren E. Wilson, Melissa A. Greiner, Lisa P. Spees, Jessica E. Pritchard, Tian Zhang, Craig E. Pollack, et al. “Patient, provider, and hospital factors associated with oral anti-neoplastic agent initiation and adherence in older patients with metastatic renal cell carcinoma.” J Geriatr Oncol, February 3, 2022. https://doi.org/10.1016/j.jgo.2022.01.008.

PMID
35125336
Full Text

Pages